Bruker Corporation announced new Functional Proteomics 2.0 workflow advancements for its timsOmni mass spectrometer aimed at deeper characterization of disease-relevant proteoforms and post-translational modifications. The company said new releases of ProteoScape, OmniScape 2026b (including the OmniWave algorithm for scaled top-down proteoform identification), and GlycoScape add capabilities such as database-independent PTM discovery, eXd-enabled glycoproteomics, and AI-enhanced de novo peptide sequencing trained on more than seven million MS/MS spectra. The announcement reports these results now as newly enabled/introduced in current software releases, and does not say they were previously presented or will be presented at a future event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202602230700BIZWIRE_USPR_____20260223_BW057286) on February 23, 2026, and is solely responsible for the information contained therein.
Comments